TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting
October 03 2018 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC) announced today that it will
highlight its new TRU NIAGEN® PRO product at the NAMS Annual
Meeting 2018 in San Diego, CA, beginning today through Oct. 6.
“Aging is so much more than skin deep—down to the cellular
level. NAD (nicotinamide adenine dinucleotide) is critical for
mitochondria function, and healthy mitochondria are a vital part of
healthy living as we age,” says gynecologist and NAMS member Alyssa
Dweck, MS, MD, FACOG, Assistant Clinical Professor in the
Department of Obstetrics, Gynecology and Reproductive Science at
the Mount Sinai School of Medicine and a consultant at the Vincent
Obstetrics and Gynecology Service at Massachusetts General
Hospital. “Increasing NAD may further boost energy levels before,
during, and after the menopausal transition.”
The sole active ingredient in Tru Niagen Pro is NIAGEN®
nicotinamide riboside, a unique form of vitamin B3 clinically
proven to safely increase one’s levels of NAD (nicotinamide adenine
dinucleotide). Decreased NAD levels have been associated with many
age-related changes in overall health.
Tru Niagen team members will be at the event, available to
discuss the latest published human evidence, to register
practitioners on the new NAD education hub and discuss how they can
bring Tru Niagen Pro directly to their patients. Practitioners
should visit booth #116 early to get a complimentary bottle of Tru
Niagen Pro, as supplies are limited.
For additional information on Tru Niagen Pro, visit
practitioner.truniagen.com.
About ChromaDex:
ChromaDex Corp. is an integrated, global
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly to
consumers as TRU NIAGEN®, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN® is
helping the world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships(949) 648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor Relations(949)
600-9727briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024